Skip to main content

Table 1 Baseline characteristics of patients in different treatment-line settings

From: Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China

Characteristic

All patients(n = 211)

1st line(n = 85)

2nd line(n = 78)

≥ 3rd line(n = 48)

Median age, years (range)

53(29–88)

55(29–84)

51(32–88)

53(29–57)

 ≥65y

41(19.4)

18(21.2)

17(21.8)

6(12.5)

 <65y

170(80.6)

67(78.8)

61(78.2)

42(87.5)

Menstruation status

    

 Menopausal

141(67.1)

58(69.0)

53(67.9)

30(62.5)

 Premenopausal

70(32.9)

27(31.0)

25(32.1)

18(37.5)

ECOG PS

    

 0

73(34.6)

29(34.1)

30(38.5)

14(29.1)

 1

130(61.6)

53(62.4)

45(57.7)

32(66.7)

 2

8(3.8)

3(3.5)

3(3.8)

2(4.2)

IV stage of first diagnosis

    

 Yes

50(23.7)

27(31.8)

12(15.4)

11(22.9)

 No

161(76.3)

58(68.2)

66(84.6)

37(77.1)

Hormone receptor status

    

 ER + PgR+

165(78.2)

71(83.5)

57(73.1)

37(77.1)

 ER + PgR-

46(21.8)

14(16.5)

21(26.9)

11(22.9)

ER status

    

 ≥ 50%

182(86.3)

70(82.4)

70(89.7)

42(87.5)

 <50%

29(13.7)

15(17.6)

8(10.3)

6(12.5)

Sensitivity to ET

    

 Sensitivity

94(44.6)

53(62.4)

26(33.3)

15(31.3)

 Acquired resistance

92(43.6)

28(32.9)

39(50.0)

25(52.0)

 Primary resistance

25(11.8)

4(4.7)

13(16.7)

8(16.7)

Number of metastatic sites

    

 ≥3

69(32.7)

20(23.5)

28(35.9)

21(43.7)

 <3

142(67.3)

65(76.5)

50(64.1)

27(56.3)

Presence of visceral metastasis

    

 Yes

134(63.5)

44(51.8)

52(66.7)

38(79.2)

 No

77(36.5)

41(48.2)

26(33.3)

10(20.8)

Metastatic sites

    

 Bone only

42(19.9)

20(23.5)

16(20.5)

6(12.5)

 Lung involvement

72(34.1)

25(29.4)

27(34.6)

20(41.7)

 Liver involvement

78(37.0)

24(28.2)

29(37.2)

25(52.1)

 Brain involvement

15(7.1)

3(3.5)

6(7.7)

6(12.6)

 Bone marrow

3(1.4)

2(2.4)

1(1.3)

-

Concomitant ET

    

 FULV

95(45.0)

35(41.2)

43(55.1)

17(35.4)

 AI

112(53.1)

47(55.3)

34(43.6)

31(64.6)

 TAM/TORE

4(1.9)

3(3.5)

1(1.3)

-

  1. Values are presented as number (%) unless otherwise indicated. ECOG, Eastern Cooperative Oncology Group; ER, Estrogen receptor; PgR, Progesterone receptor; ET, Endocrine therapy; FULV, Fulvestrant; AI, Aromatase Inhibitors; TAM, Tamoxifen; TORE, Toremifene